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Abstract
Fatigue is a common symptom in patients with rheumatoid arthritis (RA) and in patients with cancer (CA). The aim was to 
investigate the degree of fatigue in RA patients as compared to CA patients as well as potential influencing factors on RA-
related fatigue. This was a retrospective analyses of two prospective cohort studies that used the EORTC QLQ-FA12 as a 
common instrument to assess fatigue. The cohort of RA patients was based on a nationwide survey in Germany. The cohort 
of CA patients was recruited in the context of an international validation field study. Multivariable ANCOVAs compared 
levels of fatigue between the two cohorts, also including various subgroup analyses. Regression analyses explored influenc-
ing factors on RA patients’ fatigue. Data of n = 705 RA patients and of n = 943 CA patients were available for analyses. 
RA patients reported significantly higher Physical Fatigue (mean difference = 7.0, 95% CI 4.2–9.7, p < 0.001) and Social 
Sequelae (mean difference = 7.5, 95% CI 4.7–10.2, p < 0.001). CA patients reported higher Cognitive Fatigue (mean differ-
ence = 3.5, 95% CI 1.4–5.6, p = 0.001). No differences in Emotional Fatigue (p = 0.678) and Interference with Daily Life 
(p = 0.098) were found. In RA patients, mental health and pain were associated with fatigue (p values < 0.001). RA patients 
showed a considerable level of fatigue that is comparable to and in certain cases even higher than that of CA patients. The 
implementation of standardized diagnostic procedures and interventions to reduce fatigue in RA patients are recommended.
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Introduction
Fatigue is common in patients with rheumatoid arthritis 
(RA) as well as in patients with cancer (CA). Fatigue is 
defined as a condition of unusual tiredness, weakness, and 
exhaustion and considerably reduces the quality of life of 
patients [1].
In patients with RA, fatigue has an estimated prevalence 
of 40% to 70% and appears in all stages of the disease and 
during the therapeutic course [2]. The exact mechanism 
leading to fatigue in RA is unclear. Inflammation is thought 
to play an important role [3]. Fatigue is associated with the 
severity of pain and psychosocial factors such as depression 
[4]. Thus, a complex interaction of clinical factors such as 
disease activity, pain, and disability as well as of psychoso-
cial and personal factors such as coping, working, beliefs, 
and behaviors have to be taken into account [2, 5, 6]. Since 
2006, fatigue has been included as an important outcome 
measure in RA by the “Outcome Measures in Rheumatoid 
Arthritis Clinical Trials” (OMERACT) [7]. In randomized 
controlled trials, biologic disease-modifying anti-rheu-
matic drugs (DMARDs) and targeted synthetic DMARDs 
have been shown to have a moderate effect on improving 
fatigue by reducing pain and inflammation [2, 8]. Current 
evidence supports physical activity and cognitive behavioral 
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interventions as the most promising approaches to reduce 
fatigue [9].
Numerous patient-reported outcome measures (PROM) 
are available to assess RA-related fatigue, including Func-
tional Assessment of Cancer Therapy (FACT), Patient-
Reported Outcomes Measurement Information System 
(PROMIS), and Rheumatoid Arthritis Impact of Disease 
(RAID) [10]. Furthermore, a core outcome set for clinical 
trials in this area has been proposed [11].
Fatigue is also a prominent symptom in patients with CA. 
Based on their systematic review and a meta-analysis of 129 
studies (N = 71,568), Al Maqbali et al. suggested an over-
all prevalence of 49% of CA-related fatigue [12]. In young 
adulthood (median of 14 years, range 5–30), one of four CA 
survivors reported fatigue [13].
Fatigue in CA patients can have multiple causes, such 
as tumor biology, therapeutic agents, comorbidities, pain, 
emotional distress, anemia, sleep disturbance, nutritional 
deficits, or reduced functional status [14, 15]. Therefore, 
any decisions to alleviate fatigue have to be based on care-
ful differential diagnostics [16]. As for RA, there is still no 
clear pathogenetic model to explain CA-related fatigue, 
albeit some hypothetical pathways have been discussed in 
the literature [17].
Diagnostic procedures should include a patient’s medical 
history as well as a structured interview [18]. In this context, 
validated fatigue questionnaires are crucial [19], such as the 
newly developed Fatigue Module of the European Organiza-
tion for Research and Treatment of Cancer (EORTC QLQ-
FA12) [20–22].
The goal of the present project was to investigate the 
degree of fatigue in RA patients as compared to CA patients 
using the EORTC QLQ-FA12. As this is the first study 
addressing this research question, and as the samples of RA 
and CA patients included subsamples with varying disease 
states, we had no clear-cut a priori hypotheses. We, there-
fore, proceeded with an exploratory approach. Moreover, the 
influence of age, sex, pain, disease activity, mental health, 
lifestyle, and medication on RA-related fatigue was assessed. 
Finally, psychometric properties of FA12 were calculated 
separately for both populations.
Methods
Study design
Two independent studies used the same fatigue assessment 
allowing for comparative analyses.
Data of RA patients were taken from the representative 
nationwide German survey TRACE (Therapie bei Rheuma-
toider Arthritis Correlate und Einfluss) on adherence with 
therapy and quality of life [23]. Patient inclusion criteria 
were confirmed diagnosis of RA, ongoing medical treat-
ment, and ability to fill in a questionnaire in the German lan-
guage. Patients were recruited from February 2014 to Febru-
ary 2015 at 67 participating centers across Germany that are 
specialised in the treatment of RA patients; each center was 
supposed to include 10 study patients or more. The TRACE 
study was approved by the Ethics Committee of the Univer-
sity of Regensburg (reference number 13-160-0275). The 
trial was registered with study database of the German Net-
work of Health Services (VfD_TRACE_14_003438).
Data of CA patients were taken from an international 
psychometric validation study of the EORTC QLQ-FA12 
measuring CA-related fatigue in eleven European and 
non-European countries [20–22]. Inclusion criteria were 
histologically confirmed cancer of any tumor site, written 
informed consent, and the ability to understand the language 
of the questionnaire. Exclusion criteria were severe psychi-
atric or cognitive mental conditions, age below 18 years, 
currently undergoing allogeneic hematological stem cell 
transplantation (HSCT) or neoadjuvant therapy. Patients 
were recruited from February 2011 to November 2014. 
National and local ethics approvals were obtained for the 
recruiting centers (reference number of leading Ethics Com-
mittee of the University of Freiburg 165/11). The study was 
registered with the German Clinical Trial Studies Registry 
(DRKS00003091).
Both studies were conducted in compliance with the Dec-
laration of Helsinki and patients gave their written informed 
consent.
Fatigue assessment
The questionnaire assesses five fatigue dimensions: Physical 
Fatigue, Emotional Fatigue, Cognitive Fatigue, Interference 
with Daily Life, and Social Sequelae. The subscales Physi-
cal, Emotional, and Cognitive Fatigue are multi-item scales, 
Interference with Daily Life and Social Sequelae are single 
items. All scores range from 0 to 100, and higher scores 
represent a higher symptom burden. Validation studies of the 
EORTC QLQ-FA12 showed excellent reliability, validity, 
and sensitivity to change [20, 22].
Additional data
Sociodemographic (age and sex) information was recorded 
in both studies.
For CA patients, clinical information regarding tumor 
site, metastases, as well as the type and state of therapy were 
assessed and available for analyses in this study.
For RA-related fatigue, several potential influencing fac-
tors were recorded, such as disease activity, mental health, 
medication, current smoking, and physical activity [2, 8, 9].
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The validated Disease Activity Score 28 (DAS28) was 
used to measure the inflammatory activity of RA [24–26]. 
DAS28 includes assessment of the number of swollen as 
well as tender joints, measurements of the erythrocyte 
sedimentation rate as well as of the C reactive protein, and 
patient self-reported assessment of global health. DAS28 
values range from 0 to 10, and higher values represent higher 
disease activity. DAS28 < 3.2 is interpreted as remission or 
low disease activity, and ≥ 3.2 as moderate or high disease 
activity.
Short-Form-Health-Survey (SF-12, version 2) was used 
to measure health-related quality of life in terms of Physical 
and Mental Health [27, 28]. Mental Health includes emo-
tional role functioning, mental well-being, negative affect, 
and social functioning. Physical Health includes general 
health perception, physical functioning, physical role func-
tioning, and pain. Both scales range from 0 to 100, and 
higher values represent better health.
The Lifestyle Score was composed of alcohol consump-
tion (1 = yes, seldom to daily), current smoking (1 = yes, 
occasional or regularly), physical exercise (1 = no), and diet 
(1 = primarily traditional German Food). The summary score 
ranged from 0 to 4, and higher scores represent a less healthy 
lifestyle.
Analyses
Descriptive analyses included frequency (n), percentage 
(%), mean (m), and standard deviation (sd). Differences in 
sociodemographic variables between RA and CA patients 
were calculated using Chi-square test or independent t test, 
where applicable.
Differences in fatigue dimension scores between RA and 
CA patients were assessed using ANCOVAs (analysis of 
covariance). Sex and age were included as covariates in the 
ANCOVA models.
Two different ANCOVA models were computed. Model 1 
included disease main group comparisons between RA and 
CA patients. Model 2 included disease subgroup analyses 
based on clinical considerations. RA patients were assigned 
to one of two subgroups according to their DAS28 score: 
1. remission or low disease activity, or 2. moderate or high 
disease activity. CA patients were assigned to one of the 
following four groups: 1. receiving first-line curative ther-
apy; 2. receiving second- or third-line palliative therapy; 3. 
survivors I (≥ 12 and ≤ 18 months after treatment with no 
evidence of cancer or recurrence); or 4. survivors II (≥ 36 
and ≤ 72 months after treatment with no evidence of can-
cer or recurrence). Least significant differences (LSD) were 
used for post-hoc tests. Adjusted means including 95% con-
fidence intervals (CI) were reported.
Multivariable linear regression analyses (enter method) 
were conducted to explore the influence of sex, age, pain 
(SF-12), Mental Health (SF-12), disease activity (DAS28, 
dichotomized), lifestyle, and medication on RA-related 
fatigue. Physical Health was not included in the model as 
pain is a component of the Physical Health score, which 
leads to a high correlation between both variables. Based on 
published data, pain seems to be the more relevant factor in 
predicting RA-related fatigue [2]. Medication was defined 
as: biologicals (no vs. yes), glucocorticoids (no vs. yes), and 
methotrexate (MTX) (no vs. yes).
Psychometric properties were assessed separately for 
both populations. Cronbach’s alphas for multi-item scales 
were computed, and values ≥ 0.70 are considered acceptable 
[29]. Convergent and discriminant validity were assessed 
by means of item-scale correlations. Acceptable indicators 
for convergent validity are correlation coefficients ≥ 0.40 
(corrected for overlap) between an item and its own scale, 
and for discriminant validity, correlation coefficients < 0.40 
between an item and another scale. A definite scaling error 
exists if an item correlated significantly less with its own 
scale than with another scale [30].
Normality of data was not tested, although QoL data 
occasionally may be skewed. Nevertheless, by default QoL 
data are presented as means ± standard deviations [31]. 
Moreover, Gaussian models are remarkably robust to viola-
tions of normality assumption [32].
The level of significance was set at p ≤ 0.05 for all tests. 
Since this was an exploratory study, no adjustments for mul-
tiple testing were made [33]. All analyses were performed 




In total, 708 RA patients had been included in the original 
TRACE study [23]. Three patients were excluded from the 
present analyses due to missing fatigue assessment, resulting 
in 705 RA patients. RA patients characteristics are presented 
in Table 1, mean age was 59.5 years (sd = 12), and the major-
ity of patients were women (73%).
In total, 946 CA patients with a broad range of tumor 
sites were included in the original study [20–22], but three 
patients were excluded due to missing fatigue assessment, 
resulting in 943 CA patients. Mean age was 58.3 years 
(sd = 13, n = 942), and the majority of patients were 
women (n = 510, 54%). Tumor sites were as follows: breast 
n = 225 (24%), head/neck n = 213 (23%), lung n = 105 
(11%), colorectal n = 90 (10%), gynecological n = 61 (6%), 
prostate n = 61 (6%), hematological n = 49 (5%), and other 
n = 145 (15%). 25% of patients had metastases (n = 232), 
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Table 1  Characteristics of 
patients with rheumatoid 
arthritis (N = 705)






 Yes, daily 23 (3.3%)
 Yes, several times a week 48 (6.8%)
 Yes, once a week 113 (16.0%)
 Yes, once a month 59 (8.4%)




 Yes, regularly 90 (12.8%)
 Yes, occasionally 47 (6.7%)
 No, ex-smoker 88 (12.5%)
 No 475 (67.4%)
 Missing 5 (0.7%)
Physical exercise; No. (%)
 No 227 (32.2%)
 Yes, once a week for 45 min 183 (26.0%)
 Yes, twice a week for 45 min 127 (18.0%)
 Yes, three times a week for 45 min 77 (10.9%)
 More often 79 (11.2%)
 Missing 12 (1.7%)
Food; No. (%)
 Primarily traditional German food 444 (63.0%)
 Primarily Mediterranean food 172 (24.4%)
 Primarily vegetarian food 41 (5.8%)
 Missing 48 (6.8%)
Lifestyle Scorea; Mean ± SD (range) 1.8 ± 1.0 (0–4, n = 641)
DAS28; mean ± SD (range) 2.8 ± 1.2 (0–7, n = 679)
DAS28; No. (%)
 Remission or low disease activity 456 (64.7%)
 Moderate or high disease activity 223 (31.6%)
 Missing 26 (3.7%)
Mental Health (SF-12); Mean ± SD (range) 48.2 ± 11.4 (17.3–69.8, n = 603)
Physical Health (SF-12);  Mean ± SD (range) 41.7 ± 10.6 (15.1–63.0, n = 603)
Pain (SF-12); No. (%)
 Not at all 202 (28.7%)
 A little 206 (29.2%)
 Moderately 165 (23.4%)











whereas 71% (n = 668) had no metastases, and for 5% 
(n = 43) information was missing.
The two patient groups differed significantly in sex 
(p < 0.001) but not in age (p = 0.057).
Differences in fatigue
ANCOVAs were used to compare fatigue dimensions 
between disease groups adjusted for sex and age. Two 
definitions of disease groups were used. Model 1 included 
two main groups: RA patients (n = 705) vs. CA patients 
(n = 943). To account for clinical status, model 2 included 
six subgroups: 1. RA patients in remission or with low 
disease activity (n = 456), 2. RA patients with moderate 
or high disease activity (n = 223), 3. CA patients receiv-
ing first-line therapy (n = 309), 4. CA patients receiving 
second- or third-line therapy (n = 222), 5. CA survivors I 
(≥ 12 and ≤ 18 months after treatment with no evidence 
of cancer or recurrence, n = 212), and 6. CA survivors II 
(≥ 36 and ≤ 72 months after treatment with no evidence 
of cancer or recurrence, n = 198). For 26 RA and for 2 CA 
patients clinical information (DAS28/therapy) was miss-
ing, thus they were excluded from model 2.
Model 1
RA and CA patients significantly differed in Physical 
Fatigue, Cognitive Fatigue, and Social Sequelae (Table 2). 
RA patients reported significantly higher Physical Fatigue 
(mean difference = 7.0, 95% CI 4.2–9.7, p < 0.001) and 
Social Sequelae (mean difference = 7.5, 95% CI 4.7–10.2, 
p < 0.001) than CA patients. CA patients reported higher 
Cognitive Fatigue impairment than RA patients (mean dif-
ference = 3.5, 95% CI 1.4–5.6, p = 0.001). No differences 
in Emotional Fatigue (p = 0.678) and Interference with 
Daily Life (p = 0.098) were found between the two patient 
groups.
Model 2
Table 2 present differences in fatigue dimensions between 
disease subgroups. RA patients with moderate/high disease 
activity reported higher Physical (p < 0.001), Emotional 
(p < 0.001), and Cognitive (p = 0.069) Fatigue as well as 
Interference with Daily Life (p < 0.001) and Social Sequelae 
(p < 0.001) than RA patients in remission/with low disease 
activity.
Within subgroups of CA patients, patients receiving 
second- or third-line therapy reported highest interference 
with fatigue dimensions compared to the other CA patient 
subgroups (p values < 0.05), except for Social Sequelae. CA 
survivors I and II did not significantly differ in any fatigue 
dimension (p values > 0.05). Patients receiving first-line 
therapy reported higher impairment of Emotional Fatigue 
than CA survivors I and II (p values < 0.05). CA survivors I 
reported higher impairment of Social Sequelae than patients 
receiving curative therapy (p = 0.035).
RA patients in remission/with low disease activity 
reported impairment in Emotional Fatigue and Social Seque-
lae comparable to those of CA survivors I and II, but sig-
nificantly lower Emotional Fatigue impairment and higher 
Social Sequelae impairment than CA patients in both ther-
apy groups (p values < 0.05). Moreover, Physical Fatigue 
was significantly higher in RA patients in remission/with 
low disease activity than in CA patients receiving first-line 
therapy as well as in CA survivors I and II (p values < 0.05). 
CA patients receiving second- or third-line therapy reported 
higher Physical Fatigue as well as Interference with Daily 
Life than RA patients in remission/with low disease activ-
ity (p values < 0.01). Cognitive Fatigue values were signifi-
cantly lower in RA patients in remission/with low disease 
activity than in CA patients receiving second- or third-line 
therapy as well as in CA survivors I and II (p values < 0.05).
RA patients with moderate/high disease activity 
reported comparable Physical and Emotional Fatigue val-
ues (p values < 0.05), and lower impairment in Cognitive 
Fatigue (p = 0.014) as well as Interference with Daily Life 
a Data from four single lifestyle factors alcohol, smoking, physical exercise, and food were combined to a 
score ranging from 0 to 4, whereas a higher score represents a less healthy lifestyle




Length of patient-physician relationship; No. (%)
 Up to 6 months 64 (9.1%)
 Up to 1 year 48 (6.8%)
 Up to 2 years 111 (15.7%)






































































































































































































































































































































































































































































































































































































































































































































































































































































(p = 0.001) than CA patients receiving second- or third-line 
therapy. Social Sequelae was significantly higher in RA 
patients with moderate/high disease activity than in all CA 
subgroups (p values < 0.001). Moreover, RA patients with 
moderate/high disease activity reported higher impairment 
in Physical Fatigue, Emotional Fatigue, and Interference 
with Daily Life than CA patients receiving first-line ther-
apy and CA survivors I and II (p values < 0.05). Cognitive 
Fatigue was comparable in RA patients with moderate/high 
disease activity and CA patients receiving first-line therapy 
as well as CA survivors I and II (p values > 0.05).
Predictors of RA‑related fatigue
Multivariable regression analyses showed that Mental 
Health (SF-12) was constantly associated with all five 
fatigue dimensions (Table 3). With increasing Mental Health 
scores (better health), the fatigue scores decreased (less 
symptom burden) (p values < 0.001). Pain (SF-12) was sig-
nificantly associated with four out of five fatigue dimensions 
(Physical, Emotional as well as Cognitive Fatigue, and Inter-
ference with Daily Life). With increasing pain, the fatigue 
scores increased (more symptom burden) (p values < 0.001, 
Table 3). Patients taking glucocorticoids reported on aver-
age 4.6 (95% CI 1.6–7.7) higher Emotional Fatigue than 
patients who did not (p = 0.003). With increasing lifestyle 
scores (less healthy lifestyle), the Interference with Daily 
life decreased (p = 0.040). With increasing age, the Social 
Sequalae decreased (p = 0.012). No further, significant asso-
ciations were found (Table 3).
Psychometric properties
We obtained acceptable to excellent internal consistencies 
of multi-item scales of the EORTC QLQ-FA12, which were 
practically identical for RA (Cronbach’s alphas = 0.74–0.92) 
and for CA patients (Cronbach’s alphas = 0.81–0.90) 
(Table 4). Moreover, the proposed scale structure of the 
multi-item scales were confirmed in both samples (Table 4).
Discussion
A major finding of the present study was that Physical 
Fatigue was higher in RA patients than in CA patients. The 
highest level of Physical Fatigue was found in RA patients 
with high disease activity, which was even slightly higher 
than that of CA patients with second- or third-line therapy. 
RA patients also reported a higher degree of Social Seque-
lae, and again the highest means were found in RA patients 
with high disease activity.
One reason for the relatively lower fatigue values of 
CA patients than those of RA patients may be awareness 
Table 3  Predictors of rheumatoid arthritis related fatigue
Five multivariable regression analyses were conducted; require-
ments were checked and outliers defined by standardized residuals > 3 
excluded from analyses. DAS28 was entered dichotomously: refer-
ence category was remission or low disease activity. Reference cat-
B 95% CI p
Physical fatigue (N = 521)
 Age − 0.12 − 0.25 0.01 0.080
 Sex 1.77 − 1.88 5.42 0.341
 DAS28 − 1.03 − 4.55 2.49 0.566
 Pain (SF-12) 9.42 7.78 11.06  < 0.001
 Mental health (SF-12) − 1.27 − 1.42 − 1.12  < 0.001
 Lifestyle 0.06 − 1.52 1.63 0.945
 Biologicals 2.64 − 0.58 5.85 0.108
 Glucocorticoids 2.02 − 1.16 5.21 0.212
 Methotrexate − 1.48 − 4.66 1.69 0.359
Emotional fatigue (N = 519)
 Age − 0.05 − 0.18 0.07 0.416
 Sex − 0.45 − 3.91 3.01 0.800
 DAS28 1.19 − 2.16 4.54 0.486
 Pain (SF-12) 5.93 4.38 7.49  < 0.001
 Mental health (SF-12) − 1.56 − 1.70 − 1.41  < 0.001
 Lifestyle 0.37 − 1.12 1.86 0.630
 Biologicals 2.06 − 1.00 5.12 0.187
 Glucocorticoids 4.64 1.61 7.67 0.003
 Methotrexate 0.13 − 2.89 3.15 0.933
Cognitive fatigue (N = 511)
 Age − 0.05 − 0.15 0.05 0.320
 Sex − 1.42 − 4.16 1.32 0.310
 DAS28 − 0.92 − 3.59 1.75 0.498
 Pain (SF-12) 2.44 1.20 3.68  < 0.001
 Mental Health (SF-12) − 0.69 − 0.81 − .58  < 0.001
 Lifestyle − 0.79 − 1.98 0.40 0.193
 Biologicals 0.20 − 2.24 2.64 0.870
 Glucocorticoids − 0.03 − 2.45 2.38 0.979
 Methotrexate 1.97 − 0.44 4.37 0.109
Interference with daily life (N = 509)
 Age − 0.18 − 0.37 0.00 0.056
 Sex − 0.47 − 5.57 4.64 0.858
 DAS28 − 0.19 − 5.15 4.76 0.939
 Pain (SF-12) 6.74 4.45 9.04  < 0.001
 Mental health (SF-12) − 1.34 − 1.55 − 1.13  < 0.001
 Lifestyle − 2.32 − 4.54 − 0.10 0.040
 Biologicals 3.71 − 0.81 8.23 0.107
 Glucocorticoids 0.41 − 4.08 4.90 0.858
 Methotrexate − 1.43 − 5.89 3.02 0.528
Social sequelae (N = 496)
 Age − 0.23 − 0.42 − 0.05 0.012
 Sex − 4.00 − 8.96 0.95 0.113
 DAS28 1.46 − 3.36 6.29 0.552
 Pain (SF-12) 1.97 − 0.26 4.20 0.083
 Mental health (SF-12) − 1.39 − 1.60 − 1.19  < 0.001
 Lifestyle 0.57 − 1.57 2.72 0.599
 Biologicals 2.50 − 1.88 6.89 0.262
 Glucocorticoids 3.92 − 0.43 8.28 0.077
 Methotrexate 1.40 − 2.92 5.72 0.525
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of the topic and research activity in the CA community. 
According to Maqbali et al. [12], who compared studies on 
the prevalence of CA-related fatigue published from 1996 
to 2000 with studies published from 2016 to 2020, preva-
lence of CA-related fatigue has decreased over the years, 
probably due to the fact that several clinical guidelines 
have been published on the assessment and management 
of CA-related fatigue [15, 34, 35]. Most oncological and 
related guidelines refer to fatigue [36–41]. In addition, 
evidence-based Self-Help-Management-Programs for CA 
patients have become available [42–44].
Another reason for CA/RA differences in fatigue may 
be due to pathophysiology. Fatigue was higher in RA 
patients with moderate/high disease activity than in RA 
patients with remission/low disease activity. For four out 
of five fatigue dimensions, the mean difference was around 
10 score points or higher (Physical, Emotional, Interfer-
ence with Daily Life, Social Sequalae).
As fatigue is a complex and multifactorial process in all 
disease groups, possible differences in fatigue-influencing 
factors (e.g., different ongoing treatments, somatic comor-
bidities, pain, depression, anxiety, decreased functional 
status) may exist, thus affecting the results.
A slightly different picture emerged regarding Cognitive 
Fatigue. Here, on average, CA patients scored higher than 
RA patients, with CA patients undergoing second- or third-
line care yielding the highest scores. One reason for this 
may be that CA patients frequently complain about neu-
ropsychological deficits due to adjuvant therapy. However, 
it is difficult to differentiate between Cognitive Fatigue and 
CA-related cognitive impairment (chemotherapy-related 
cognitive impairment [CRCI], Chemobrain). For this pur-
pose, additional neuropsychological assessment would have 
been necessary, which was not focus of this study. CRCI can 
occur during or after chemotherapy and represents a concern 
for many patients with CA [45], but possibly not for patients 
with RA because of the different treatment, although some 
drugs like methotrexate are used for RA and CA.
CA patients undergoing second- or third-line therapy also 
had high scores regarding Interference with Daily Life and 
Emotional Fatigue, followed by RA patients with high dis-
ease activity. On average, RA and CA patients did not differ 
in Interference with Daily Life and Emotional Fatigue.
Given the high overall fatigue level in RA patients, we 
conducted regression analyses to explore potential influenc-
ing variables. We found that Mental Health and Pain were 
associated with all or most fatigue dimensions. In our study, 
medication did not play a role regarding fatigue, except for 
glucocorticoids, which led to higher Emotional Fatigue 
than in patients who did not take glucocorticoids. This cor-
relation may be explained by the fact that glucocorticoids 
influence psychiatric and cognitive functions and cause 
egories for the other dichotomous variables were: sex = male, medica-
tion defined as biologicals, glucocorticoids, methotrexate = no
Bold values denote statistical significance at the p ≤ 0.05 level
Table 3  (continued)
Table 4  Reliability, convergent 
and discriminant validity of 
EORTC QLQ-FA12 of patients 
with rheumatoid arthritis and 
cancer
RA rheumatoid arthritis patients (N = 705), CA cancer patients (N = 943). The actual number of patients was 
occasionally smaller because of missing values
Cronbach’s alpha values for multi-item scales were > 0.70 in both populations and are considered accept-
able indicators for internal consistency [29]. Correlation coefficients supported convergent validity (item-
own-scale correlations coefficients ≥ 0.40; corrected for overlap, italic values) and discriminant validity 
(item-other-scale correlations coefficients < 0.40 or no definite scaling error) in both populations [30]










RA CA RA CA RA CA RA CA RA CA
1 0.82 0.82 0.69 0.50 0.45 0.44 0.66 0.69 0.51 0.34
2 0.85 0.81 0.69 0.53 0.46 0.47 0.67 0.71 0.49 0.35
3 0.79 0.77 0.70 0.47 0.45 0.47 0.63 0.68 0.45 0.32
4 0.72 0.68 0.62 0.45 0.45 0.44 0.76 0.61 0.51 0.34
5 0.79 0.73 0.74 0.56 0.53 0.50 0.68 0.62 0.52 0.34
6 0.76 0.54 0.81 0.72 0.61 0.45 0.60 0.48 0.53 0.34
7 0.70 0.51 0.83 0.74 0.61 0.41 0.55 0.49 0.48 0.28
8 0.73 0.49 0.82 0.71 0.59 0.44 0.57 0.44 0.54 0.38
9 0.59 0.55 0.67 0.47 0.64 0.69 0.53 0.43 0.48 0.40
10 0.35 0.45 0.49 0.44 0.64 0.69 0.36 0.41 0.37 0.38
11 0.78 0.78 0.62 0.54 0.50 0.46 – – 0.63 0.37
12 0.57 0.40 0.55 0.38 0.48 0.42 0.63 0.37 – –
Cronbach’s alpha 0.92 0.90 0.91 0.85 0.74 0.81 – – – –
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sleep disturbances [46]. When entered into a multivariable 
model, the effect of disease activity (DAS28) vanished. This 
observation is in line with previous studies that identified 
pain and psychosocial factors to be more important for the 
development of fatigue than disease activity [4, 47]. Thus, 
the differences in fatigue found between our RA patients 
with moderate/high vs. low disease may be due to underly-
ing factors that are closely connected with disease activity.
To our knowledge, this is the first study that directly com-
pared fatigue levels in RA and CA patients. A qualitative 
meta-analysis explored fatigue sensations in different non-
CA patient populations, such as RA, chronic kidney dis-
ease, chronic obstructive pulmonary disease, heart failure, 
and multiple sclerosis [1].This analysis found that fatigue 
was common across these diseases and diminished patients’ 
quality of life. The present study adds important informa-
tion regarding quantitative differences and showed that RA 
patients, on average, were worse off than CA patients in two 
out of five fatigue dimensions. In some sense, the present 
project follows the rationale of the famous Medical Outcome 
Study (MOS), which investigated variations in patient out-
comes in different disease groups such as diabetes, hyperten-
sion, and coronary heart disease [48].
The present study also showed that the EORTC QLQ-
FA12, developed to assess fatigue in CA patients, is also a 
suitable questionnaire with appropriate psychometric prop-
erties for RA patients. Internal consistencies as well as con-
vergent and discriminant validity of the multi-item scales 
were comparably high in both populations. Moreover, the 
EORTC QLQ-FA12 was able to distinguish between groups 
of different disease burden.
One limiting factor of the present analysis is that RA 
patients were entirely German in contrast to CA patients 
who came from eleven European and Non-European coun-
tries. Therefore, the generalizability of the psychometric 
results is limited. However, the psychometrics were similar 
to the ones found in the international sample of CA patients. 
Therefore, we interpret our results with a high degree of 
confidence. A strength of this project was the high number 
of patients, which allowed to reliably investigate subgroup 
comparisons.
Another limiting factor of this study was that data 
were based on two studies that were originally designed 
for different aims. The TRACE study investigated adher-
ence with therapy and quality of life of patients with RA, 
and the EORTC study was conducted as an international 
validation study of the QLQ-FA12. Therefore, numerous 
clinical variables that would have been of interest in the 
present analyses (e.g., anemia, specifics of cancer medi-
cation) were not available. Nevertheless, these potential 
“confounding” factors can be thought of as characteris-
tics of the study populations under investigation. This 
was exactly the purpose of this project: approaching two 
patient groups (RA and CA) with all their known and 
unknown characteristics and exploring their differences 
with regard to quality of life.
Conclusion
The fatigue level of RA patients should be regarded as 
alarming, because it was comparable to and sometimes 
even higher than that of CA patients. There is an urgent 
need to generate more knowledge on RA-related fatigue. 
To start with, the implementation of current standardized 
diagnostic procedures and interventions to reduce fatigue 
in RA patients are recommended. This study also showed 
that the EORTC QLQ-FA12, developed to measure fatigue 
in CA patients, is also suitable and reliable for RA patients.
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